ReviewNature biomedical engineering2021
The evolution of commercial drug delivery technologies.
Review in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 444 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
444 citing papers in PubMed.
- A novel approach to improving solubility of drugs: chelation-assisted solubility enhancement (CHASE).Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Stimuli-responsive structural transformation of adaptive peptide nanomaterials toward biomedical applications.Materials today. Bio · 2026Review
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Detaching Photosensitive Nanoparticles from Cells Prevents Them from Remaining in Cells after Photoporation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Terpesomes as Advanced Nanocarriers for Enhanced Drug Delivery: Formulation Strategies, Mechanistic Insights, and Therapeutic Applications.AAPS PharmSciTech · 2026Review
- Preparation of placenta-tropic mRNA lipid nanoparticles for pregnancy disorders.Nature protocols · 2026Review
- Review
- Advances in Polymeric Drug Delivery Systems.Pharmaceutics · 2026Article
- Erythrocyte Membrane Incorporation Modulates the Stability and Fusion-Associated Behavior of Biomimetic Liposomes.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- ICAM-1 targeting of nanocarriers in a human blood-brain-barrier-on-a-chip complementsJournal of drug targeting · 2026Article
- Revisiting Colloid Theory for Biomedicine: Reconciling Simple Models in Complex Environments.ACS nano medicine · 2026Article
- Breaking barriers: nano-boosted drug delivery systems in overcoming the defenses of pancreatic cancer.Molecular cancer · 2026Review
- Article
- Tyrosine-capped gold nanoparticles enable cysteine-free peptide loading, enhancing the antipseudomonal efficacy of scorpion-derived AamAP1-Lys-NHJournal of materials chemistry. B · 2026Article
- Coronamicroparticle Arrays with Stable Superamphiphobicity.Small methods · 2026Article
- Mechanically Triggered DNA Nanovehicles for Targeted Dual-Drug Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanotransduction in Marfan Syndrome and Related Aortic Disorders: Insights from Transcriptomic Analyses.Genes · 2026Review
- A Nanoparticle-Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable next-generation supramolecular self-assembled materials as drug delivery systems.Bioactive materials · 2026Review
- Prospects and challenges in intracellular delivery of therapeutic proteins.Pharmacological reports : PR · 2026Review
384 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Drug delivery technologies have enabled the development of many pharmaceutical products that improve patient health by enhancing the delivery of a therapeutic to its target site, minimizing off-target accumulation and facilitating patient compliance. As therapeutic modalities expanded beyond small molecules to include nucleic acids, peptides, proteins and antibodies, drug delivery technologies were adapted to address the challenges that emerged. In this Review Article, we discuss seminal approaches that led to the development of successful therapeutic products involving small molecules and macromolecules, identify three drug delivery paradigms that form the basis of contemporary drug delivery and discuss how they have aided the initial clinical successes of each class of therapeutic. We also outline how the paradigms will contribute to the delivery of live-cell therapies.
Indexed as
Identifiers
33795852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.